ZYNE, when and how...
Updated
Zynerba is one of my favourite biopharma stocks. I've played her from $3.88 up to $5.22, then sold when I saw that the hype was temporarily over.
I didn't want to go long ZYNE, because biopharma is some scary stuff. When they presented failed trials earlier, the stock plunged 53%. On the other hand, when a trial succeeds, and a medicine can be filed and prepped for marketing, it is a potential almost without limits.
ZYNE has a patent gel, which is important, because it is hard to get CBD into your body if you don't want to smoke or eat it.
I was just looking at GW PHarma... Second one out, first one with epilepsy medicine...
Zynerba is expected to break even this year. Current trial phases are published on their website. Short term, I don't see much of a bullish trend, just investors getting on board at specific publications.
My plan is to wait for it to reach, what I see as, the buy zone. I'm planning to take a moderate position there.
I didn't want to go long ZYNE, because biopharma is some scary stuff. When they presented failed trials earlier, the stock plunged 53%. On the other hand, when a trial succeeds, and a medicine can be filed and prepped for marketing, it is a potential almost without limits.
ZYNE has a patent gel, which is important, because it is hard to get CBD into your body if you don't want to smoke or eat it.
I was just looking at GW PHarma... Second one out, first one with epilepsy medicine...
Zynerba is expected to break even this year. Current trial phases are published on their website. Short term, I don't see much of a bullish trend, just investors getting on board at specific publications.
My plan is to wait for it to reach, what I see as, the buy zone. I'm planning to take a moderate position there.
Note
Gosh, did I miss out on this one...
🅱🄰🆁🅺🆆🄾🆁🆃🅷
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.